Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter to the Editor - Observation Letter
2020:86:6;688-690
doi: 10.4103/ijdvl.IJDVL_918_19
PMID: 33159027

Ponatinib-induced atypical pityriasis rubra pilaris-like rash

Divya Kamat1 , Debajyoti Chatterjee2 , Rahul Mahajan1
1 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Rahul Mahajan
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh
India
Published: 28-Oct-2020
How to cite this article:
Kamat D, Chatterjee D, Mahajan R. Ponatinib-induced atypical pityriasis rubra pilaris-like rash. Indian J Dermatol Venereol Leprol 2020;86:688-690
Copyright: (C)2020 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

The introduction of targeted chemotherapeutic agents like tyrosine kinase inhibitors elicit more selective anti-cancer effects and have lesser systemic toxicities when compared to traditional chemotherapeutic agents. Ponatinib, a third generation tyrosine kinase inhibitor, was approved by Food and Drug Administration (FDA) in 2012 for treatment refractory chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia.[1],[2] We present a patient with refractory CML who presented with an atypical skin rash after institution of ponatinib.

A 52-year-old woman presented to our out-patient department with complaints of an itchy skin eruption of one month duration. She had been diagnosed with BCR/ABL positive chronic myeloid leukemia 2 years back, but had failed to respond to the first line treatment. Oral Ponatinib 45mg once daily was thus initiated. Three weeks after starting the drug, she developed redness and itchy eruption initially over face and forearms which gradually extended to involve the trunk. Examination revealed multiple reddish folliculo centric papules distributed symmetrically over the trunk and upper arms resembling keratosis pilaris [Figure - 1]a and [Figure - 1]b. Irregular icthyosiform atrophic plaques were seen over the upper chest and neck with islands of sparing [Figure - 1]c. Dorsum of hands, forearms and legs had a diffuse atrophic wrinkled appearance. However, palmoplantar keratoderma was conspicuously absent. Dermatoscopy highlighted the yellow orange areas with red dotted vessels and thin scales [Figure - 2]a. Histopathology showed follicular plugging, alternative orthokeratosis and parakeratosis, lymphocytic exocytosis and focal interface activity [Figure - 2]b. A diagnosis of atypical pityriasis rubra pilaris (PRP)-like rash was thus made and topical tazarotene 0.05% cream was advised to be applied once daily over the forearms. There was no photosensitivity following topical application of tazarotene. Due to progressive lesions, oral acitretin 25 mg once daily was added without discontinuing ponatinib. Tazarotene was stopped due to extensive involvement and emollients were prescribed instead. After 2 weeks of treatment with acitretin, there was significant response with near complete resolution of the folliculocentric and icthyotic lesions [Figure - 1]d Acitretin was further continued along with ponatinib. Acitretin was continued for 10 weeks following which patient was lost to follow up. The dose was maintained at 25 mg once daily and was not hiked as there was satisfactory improvement with this.

The best evidence regarding frequency and management of skin toxicity due to ponatinib comes from few large randomized controlled trials such as the PACE trial in which dermatologic specific adverse effects were reported to be rash (47%) and dry skin (42%).[3] The mechanism of these icthyosiform eruptions has been poorly elucidated. Another common cutaneous eruption reported with tyrosine kinase inhibitors is keratosis pilaris-like lesions which are also seen with Rapidly Accelerated Fibrosarcoma Gene (RAF) inhibitors. In addition to being a tyrosine kinase inhibitor, ponatinib also causes 'off target' inhibition of various other signaling pathways like fibroblast growth factor, platelet derived growth factor and sarcoma (SRC) family proteins amongst others. This might account for the similarity of cutaneous eruptions seen with other multikinase inhibitors.[4]

The index case had a type 2 PRP-like rash similar to the previously reported cases.[4],[5] Most of these cases had favorable response to treatment without discontinuing Ponatinib, although one needed Ponatinib dose reduction. Treatment options include topical steroids and retinoids. For more generalized cases oral corticosteroids, oral retinoids, phototherapy or combination of these have been successfully tried as in our patient.[4],[5]

Systemic retinoids have also been used as a chemo-preventive agent in hematological malignancies, especially acute promyelocytic leukemia. All-trans retinoic acid induces differentiation of cancer stem cells and modulates the cell cycle.In vitro studies have also shown a suppressive effect of All trans retinoic acid on Ph+ cells in CML.[6] In conclusion, dermatological side effects especially icthyosiform eruptions are fairly common with ponatinib. Oral retinoids are effective for generalized PRP-like eruptions and most cases do not require discontinuation of ponatinib.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Alloo A, Sheu J, Butrynski JE, de Angelo DJ, George S, Murphy GF, et al. Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities. Br J Dermatol 2015;173:574-7.
[Google Scholar]
2.
Derlino F, Barruscotti S, Zappasodi P, Brazzelli V, Vassallo C. Ponatinib-induced widespread ichthyosiform eruption. J Eur Acad Dermatol Venereol 2017;31:e519-21.
[Google Scholar]
3.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial. Blood 2018;132:393-404.
[Google Scholar]
4.
Eber AE, Rosen A, Oberlin KE, Giubellino A, Romanelli P. Ichthyosiform pityriasis rubra pilaris-like Eruption Secondary to Ponatinib Therapy: Case report and literature review. Drug Saf Case Rep 2017;4:19.
[Google Scholar]
5.
Jack A, Mauro MJ, Ehst BD. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib. J Am Acad Dermatol 2013;69:e249-50.
[Google Scholar]
6.
Bunaciu RP, Yen A. Retinoid chemoprevention: Who can benefit? Curr Pharmacol Rep 2015;1:391-400.
[Google Scholar]

Fulltext Views
725

PDF downloads
323
Show Sections